Kan Jiang
Fuzhou, 350014, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 31, 2026
Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: January 06, 2025
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.
Journal: Therapeutic advances in medical oncology
Published: December 12, 2023
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Journal: Thoracic cancer
Published: November 27, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.
Journal: Thoracic cancer
Published: October 25, 2023
Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
Journal: Journal of neuro-oncology
Published: October 19, 2023
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
Journal: Journal of neuro-oncology
Published: September 28, 2023
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study.
Journal: BMC pulmonary medicine
Published: September 10, 2023
A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.
Journal: MedComm
Published: July 19, 2023
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 05, 2023
CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types.
Journal: Frontiers in immunology
Published: June 21, 2022
Last Updated: 09/26/2026